Sirukumab - CISMeF

Preferred Label : Sirukumab;

NCIt synonyms : Plivensia (TM);

NCIt definition : A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the pro-inflammatory cytokine interleukin-6 (IL-6), with potential immunomodulating and anti-inflammatory activities. Upon administration, sirukumab targets, binds to and blocks the activity of IL-6, which may inhibit the binding of IL-6 to its receptor interleukin-6 receptor (IL-6R). This may inhibit the IL-6/IL-6R-mediated signal transduction pathway and the associated inflammatory response.;

UNII : 640443FU93;

CAS number : 1194585-53-9;

Molecule name : CNTO 136; CNTO-136;

NCI Metathesaurus CUI : CL553575;

Détails

Origin ID

C152371;

UMLS CUI

C3254570;

Automatic exact mappings (from CISMeF team)
- Sirukumab [ICD-11 Extension code]
Currated CISMeF NLP mapping
- sirukumab [MeSH Supplementary Concept]
- sirukumab [MeSH concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- sirukumab [ATC Code]
- sirukumab [MeSH concept]
- sirukumab [MeSH Supplementary Concept]
Validated automatic mappings to BTNT
- sirukumab [ATC Code]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCIt COVID-19 Agent Terminology [NCIt concept]
- NCIt COVID-19 Terminology [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients